Related Experiment Video

Updated: Aug 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension

Yehonatan Sharabi1, Eldad Adler, Ari Shamis

  • 1Hypertension Unit and Internal Medicine D, Chaim Sheba Medical affiliated to the Chaim Sheba Medical Center, Tel Hashomer.

American Journal of Hypertension
|July 4, 2006
PubMed

Insights

Add-on spironolactone effectively lowers blood pressure in patients with uncontrolled hypertension (UH), especially those with low potassium. This aldosterone antagonist shows significant BP reduction compared to standard treatments.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Uncontrolled hypertension (UH) can stem from hyperaldosteronism.
  • Routine aldosterone antagonist use is suggested for UH.
  • This study evaluates add-on aldosterone antagonist efficacy in UH.

Purpose of the Study:

  • Assess spironolactone's effectiveness as add-on therapy for UH.
  • Identify patient characteristics that predict response to aldosterone antagonists.

Main Methods:

  • Retrospective analysis of UH patients in a hypertension clinic.
  • Compared add-on spironolactone versus other antihypertensive drugs.
  • Patients used ≥2 antihypertensive drugs prior to add-on therapy.

Main Results:

  • Spironolactone significantly reduced BP (23.2/12.5 mm Hg) vs. other drugs (7.6/5.8 mm Hg).
  • Spironolactone group had lower serum potassium (3.8 vs. 4.5 mmol/L).
  • Low serum potassium (<4 mmol/L) correlated with greater BP reduction.

Conclusions:

  • Add-on spironolactone is effective for UH, particularly in patients with low serum potassium.
  • Serum potassium may guide aldosterone antagonist use in UH management.
  • Further research is needed to define aldosterone antagonists' role in UH.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Antagonists: Pharmacological Actions of &#593;-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...